Ranibizumab news

All news on Ranibizumab (also known as Lucentis and Susvimo): plants, production capacities, investments and involved companies.

17 October 2025

Roche Unveils Phase III Data for Vamikibart in Uveitic Macular Edema

Vamikibart shows promise in treating UME, with significant vision improvements in trials, offering a non-steroid alternative with fewer side effects.
4 September 2025

Roche's Contivue with Susvimo Receives CE Mark for nAMD Treatment

Contivue with Susvimo offers continuous nAMD treatment, showing stable long-term vision outcomes with up to two refills yearly, backed by seven-year LADDER study data.

Who will be producing Ranibizumab in the future?

Find out with chemXplore Alpha

Learn more